Related Experiment Video

Updated: Aug 17, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial

Alexandre Mathy1, Paul Baas, Otilia Dalesio

  • 1Biometrics Department, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. a.mathy@nki.nl

Lung Cancer (Amsterdam, Netherlands)
|June 14, 2005
PubMed

Insights

Imatinib mesylate (Glivec) showed no significant response in malignant mesothelioma patients. While some experienced disease stabilization, further research into imatinib monotherapy for this cancer is not recommended.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Malignant mesothelioma is a rare and aggressive cancer.
  • Treatment options for malignant mesothelioma are limited, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To evaluate the efficacy and safety of imatinib mesylate as a monotherapy for patients with malignant mesothelioma.

Main Methods:

  • A clinical trial involving 25 patients with histologically confirmed malignant mesothelioma.
  • Patients received oral imatinib mesylate, starting at 400 mg/day, with a maximum dose of 800 mg/day.

Main Results:

  • No objective responses were observed in any of the patients.
  • Three patients (12%) achieved prolonged disease stabilization for over 6 months.
  • Median survival time was 398 days; median time to progression was 63 days.
  • Reported side effects were mild, including edema, nausea, constipation, and diarrhea.

Conclusions:

  • Imatinib mesylate monotherapy did not demonstrate significant efficacy in malignant mesothelioma.
  • Further clinical investigation of imatinib as a single agent for this indication is not warranted based on these findings.

More Related Videos

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...